NextCell Pharma has announced that a patent application has been filed for the treatment of Sars-CoV-2 mediated severe pneumonia with ProTrans.
NextCell increases the IP protection for the drug candidate ProTrans for the treatment of autoimmune diseases and inflammatory conditions. The latest patent application has is entitled; “Allogeneic Composition for Treatment off Covid-19”.
By using the possibility of priority from a previous application, the COVID-19 application has a priori day of August 14, 2020, i.e. dated 1 year back in time, the company states.
Based on a clinical trial
NextCell has filed a total of four international patent applications for the selection algorithm and treatment of diabetes, prediktionsalgoritmen, the treatment of the CNS, and treatment of COVID-19.
“The application is based on the clinical trials carried out with COVID-19 patients in Sweden and Canada. The time for priority is important and should provide good protection for ProTrans,” says Mathias Svahn, CEO.